
Viking Therapeutics, Inc.: updates and filings
Price
$24.77
November 20, 2026Market cap $3.2B
What Ploutos Investor adds for Viking Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 28, 2026next Jan 28, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
September 2026
July 2026
April 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 28, 2026Results of operationsForm8-K
- Sep 28, 2026Material agreement entered, new material financial obligationForm8-K
- Sep 24, 2026APPLICATION FOR DESIGNATION OF A NEW TRUSTEEForm305B2
- Sep 22, 2026Other material eventsForm8-K
- Jul 30, 2026Shelf registration for future offeringsFormS-3ASR
- Jul 29, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 29, 2026Results of operationsForm8-K
- May 26, 2026Shareholder voteForm8-K
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 29, 2026Results of operationsForm8-K
- Apr 1, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 1, 2026Additional annual meeting materialFormDEFA14A
- Apr 1, 2026Annual meeting proxy statementFormDEF 14A
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 11, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 11, 2026Results of operationsForm8-K
- Nov 5, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 23, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Oct 22, 2025Results of operationsForm8-K
- Aug 19, 2025Regulation FD disclosureForm8-K
- Aug 6, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 23, 2025Quarterly reportfor the period to Jun 30, 2025Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 29, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 28, 2026 | 8-K | Results of operations | Document |
| Sep 28, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Sep 24, 2026 | 305B2 | APPLICATION FOR DESIGNATION OF A NEW TRUSTEE | Document |
| Sep 22, 2026 | 8-K | Other material events | Document |
| Jul 30, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Jul 29, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 29, 2026 | 8-K | Results of operations | Document |
| May 26, 2026 | 8-K | Shareholder vote | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 30, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 29, 2026 | 8-K | Results of operations | Document |
| Apr 1, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 1, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 1, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 11, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 11, 2026 | 8-K | Results of operations | Document |
| Nov 5, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 23, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Oct 22, 2025 | 8-K | Results of operations | Document |
| Aug 19, 2025 | 8-K | Regulation FD disclosure | Document |
| Aug 6, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 23, 2025 | 10-Q | Quarterly reportfor the period to Jun 30, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 22, 2014.
The full analysis
What do Viking Therapeutics's filings show?
The filings are where every one of Viking Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.